Skip to main content
. 2016 Summer;9(3):158–173.

Table 3.

Summary of recent metabolomics studies in the field NAFLD

Reference Tissue Platform Decreased or increased metabolites in the patients compared to the control group
Puri P (2009) Plasma HPTLC
GCFID
LCMS
palmitoleic, oleic acids
dihomo gamma-linolenic (20:3n6) acids, Triacylglycerols, palmitoleic acid to palmitic acid (16:0) ratio
Linoleic acid
García-Canaveras JC(2011) liver UPLCESIQTOFMS hypoxanthineglutamine, γ-glutamyl-dipeptides creatinine, GCDCA , TCDCA
L-glutamyl-L-lysine, Lleucyl-L-proline, glutamate,
Kalhan SC(2011) plasma UPLCESITQMS
GCMS
carnitine, butyrylcarnitine (C5), glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine, methylbutyrylcarnitine, glycocholate, taurocholate, glycochenodeoxycholate, Mannose and lactate
glutathione, long-chain fatty acids and cysteine-glutathione
JonathanBarr(2010) serum UPLC/MS lysophosphatidylcholine (LPC),deoxycholic acid
bile acids (BAs), sphingomyelin: (SM 36:3), (d18:2/16:0), (d18:2/14:0), (d18:1/18:0), (d18:1/16:0), (d18:1/12:0), and (d18:0/16:0)
Creatine

Red color: increased metabolite

Blue color: decreased metabolite

HHS Vulnerability Disclosure